2 Penny Stocks That Wall Street Believes Can Soar Over 200%

Adverum also plans to present two-year follow-up results from the LUNA Phase 2 trial in the fourth quarter of 2025. These findings are expected to support Ixo-vec’s potential for long-term safety and efficacy in wet AMD patients. Furthermore, the company is planning to launch AQUARIUS, its second Phase 3 research, in the fourth quarter of 2025, subject to funding.CEO Laurent Fischer, M.D., emphasized, “The progress in ARTEMIS, along with growing enthusiasm among specialists, supports our confidence in Ixo-v ...